News for EDSA Stock
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
NEUPATH APPOINTS STEPHEN LEMIEUX AS PRESIDENT TO DRIVE NEXT PHASE OF STRATEGIC GROWTH
Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Edesa Biotech Reports Fiscal Year 2024 Results
Edesa Biotech’s Founder Makes Strategic Investment in the Company
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech to Participate in Upcoming Investor Conferences
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
Edesa Biotech to Participate in Barclays Global Healthcare Conference
Edesa Biotech to Participate in Upcoming Dermatology Meetings
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Edesa Biotech Reports Fiscal Year 2023 Results
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
Edesa Biotech to Present at Dermatology Drug Development Summit
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
Edesa Biotech Announces One-for-Seven Reverse Share Split
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
Edesa Biotech to Participate in Swiss Biotech Day
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Edesa Biotech Reports Fiscal Year 2022 Results
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
Edesa Biotech to Present at ARDS Drug Development Summit
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
Edesa Biotech Appoints Strategy Expert to Board of Directors
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
Edesa Biotech to Join Ontario Bioscience Panel Discussion
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
Edesa Biotech Reports Fiscal Year 2021 Results
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
Edesa Biotech Extends COVID-19 Clinical Study to Poland
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
Edesa Biotech Extends Dermatitis Study to Canada
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
Edesa Biotech Reports Favorable Review of COVID-19 Study
Edesa Biotech to Attend BIO Digital 2021
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
Edesa Biotech to Join Panel Discussion at Industry Event
Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
Edesa Biotech Expands Rights to Anti-Inflammatory Technology
Edesa Biotech Reaches Enrollment Milestone in COVID Study
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million
Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares
Edesa Biotech Reports Fiscal First Quarter 2021 Results
Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
Edesa Biotech to Join Panel Discussion at Government COVID-19 Event
Edesa Biotech Expands COVID-19 Clinical Study to Colombia
Edesa Biotech Issues Letter to Shareholders
Edesa Biotech Reports Fiscal Year 2020 Results
Edesa Biotech Enrolls First Patient in COVID-19 Study
Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study
Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.
Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc.
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
Back to Sitemap